For a Limited Time: Get 3 Years of Access at the Price of 1
Here is the latest financial fact sheet of WALPAR NUTRITIONS LTD.. For more details, see the WALPAR NUTRITIONS LTD. quarterly results and WALPAR NUTRITIONS LTD. share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 5.0 |
No. of shares | m | 4.70 |
1 Week | % | 0.0 |
1 Month | % | 0.0 |
1 Year | % | - |
52 week H/L | Rs | 154.0/66.0 |
No. of Mths Year Ending |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
WALPAR NUTRITIONS LTD. EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | NA | NA | NA | |||
Low | Rs | NA | NA | NA | |||
Sales per share (Unadj.) | Rs | 18.2 | 58.9 | 77.4 | |||
Earnings per share (Unadj.) | Rs | 0.4 | 0.8 | 1.8 | |||
Diluted earnings per share | Rs | 0.3 | 0.8 | 1.7 | |||
Cash flow per share (Unadj.) | Rs | 0.8 | 1.4 | 6.0 | |||
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | |||
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | |||
Avg Dividend yield | % | 0 | 0 | 0 | |||
Book value per share (Unadj.) | Rs | 14.3 | 24.2 | 25.8 | |||
Adj. book value per share | Rs | 10.2 | 23.4 | 25.0 | |||
Shares outstanding (eoy) | m | 3.34 | 4.54 | 4.54 | |||
Price / Sales ratio | x | 0 | 0 | 0 | |||
Avg P/E ratio | x | 0 | 0 | 0 | |||
P/CF ratio (eoy) | x | 0 | 0 | 0 | |||
Price / Book Value ratio | x | 0 | 0 | 0 | |||
Dividend payout | % | 0 | 0 | 0 | |||
Avg Mkt Cap | Rs m | 0 | 0 | 0 | |||
Total wages/salary | Rs m | 6 | 21 | 31 |
WALPAR NUTRITIONS LTD. INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 61 | 268 | 351 | |||
Other income | Rs m | 0 | 0 | 3 | |||
Total revenues | Rs m | 61 | 268 | 355 | |||
Gross profit | Rs m | 5 | 10 | 35 | |||
Depreciation | Rs m | 1 | 3 | 19 | |||
Interest | Rs m | 2 | 5 | 8 | |||
Profit before tax | Rs m | 2 | 3 | 11 | |||
Minority Interest | Rs m | 0 | 0 | 0 | |||
Prior Period Items | Rs m | 0 | 0 | 0 | |||
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | |||
Tax | Rs m | 0 | -1 | 3 | |||
Profit after tax | Rs m | 2 | 4 | 8 | |||
Gross profit margin | % | 7.5 | 3.7 | 9.9 | |||
Effective tax rate | % | 8.2 | -30.2 | 27.1 | |||
Net profit margin | % | 2.5 | 1.3 | 2.3 |
WALPAR NUTRITIONS LTD. BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 148 | 188 | 236 | |||
Current liabilities | Rs m | 85 | 138 | 146 | |||
Net working cap to sales | % | 102.8 | 18.6 | 25.6 | |||
Current ratio | x | 1.7 | 1.4 | 1.6 | |||
Inventory Days | Days | 4 | 35 | 4 | |||
Debtors Days | Days | 4,304 | 1,243 | 1,296 | |||
Net fixed assets | Rs m | 30 | 90 | 106 | |||
Share capital | Rs m | 33 | 45 | 45 | |||
"Free" reserves | Rs m | 14 | 65 | 72 | |||
Net worth | Rs m | 48 | 110 | 117 | |||
Long term debt | Rs m | 47 | 16 | 61 | |||
Total assets | Rs m | 180 | 279 | 342 | |||
Interest coverage | x | 1.9 | 1.6 | 2.4 | |||
Debt to equity ratio | x | 1.0 | 0.1 | 0.5 | |||
Sales to assets ratio | x | 0.3 | 1.0 | 1.0 | |||
Return on assets | % | 1.8 | 3.0 | 4.7 | |||
Return on equity | % | 3.1 | 3.2 | 6.9 | |||
Return on capital | % | 3.6 | 6.0 | 10.7 | |||
Exports to sales | % | 0 | 0 | 0 | |||
Imports to sales | % | 0 | 0 | 0 | |||
Exports (fob) | Rs m | 0 | 0 | 0 | |||
Imports (cif) | Rs m | 0 | 0 | 0 | |||
Fx inflow | Rs m | 0 | 0 | 0 | |||
Fx outflow | Rs m | 0 | 0 | 0 | |||
Net fx | Rs m | 0 | 0 | 0 |
WALPAR NUTRITIONS LTD. CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | -3 | -11 | 11 | |||
From Investments | Rs m | -20 | -61 | -34 | |||
From Financial Activity | Rs m | 30 | 67 | 24 | |||
Net Cashflow | Rs m | 6 | -5 | 1 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Kalpesh Ladhawala | COMP SEC: Priyanka Shah | YEAR OF INC: 2009 | NSE CODE: 99990 | FV (Rs): 10 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare WALPAR NUTRITIONS LTD. With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
On Friday, Indian share markets traded on a positive note throughout the trading session and ended higher.